Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and Taxol in Platinum-Resistant Recurrent Ovarian Cancer
NCT02440425Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Oct 2015
- Primary completion
- Apr 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in ovarian cancer, sponsored by Moffitt Cancer Center. Started Oct 2015; status: completed.
02
Drugs
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT02440425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02440425.